Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz(®)) in Europe: A Prescriber Survey
PMID: 39609366
Source: Clin Drug Investig
Publication date:
2025-07-24
Year:
2024
Abstract
NULL